Abstract
The deregulated proteolysis is associated with various diseases in humans. Proteases are commonly regarded as the therapeutic targets. Almost one-third of all proteolytic enzymes in humans are serine proteases. This work provides a brief characteristic of the proteinaceous natural inhibitors, mostly of serine proteases. The examples of some classical and recently identified canonical and noncanonical inhibitors as well as serpins are described. Their actual and potential therapeutic applications are discussed.
Keywords: Serine proteases, canonical, non-canonical inhibitors, serpins.
Current Pharmaceutical Design
Title:Natural Proteinaceous Inhibitors of Serine Proteases
Volume: 19 Issue: 6
Author(s): Dawid Debowski
Affiliation:
Keywords: Serine proteases, canonical, non-canonical inhibitors, serpins.
Abstract: The deregulated proteolysis is associated with various diseases in humans. Proteases are commonly regarded as the therapeutic targets. Almost one-third of all proteolytic enzymes in humans are serine proteases. This work provides a brief characteristic of the proteinaceous natural inhibitors, mostly of serine proteases. The examples of some classical and recently identified canonical and noncanonical inhibitors as well as serpins are described. Their actual and potential therapeutic applications are discussed.
Export Options
About this article
Cite this article as:
Debowski Dawid, Natural Proteinaceous Inhibitors of Serine Proteases, Current Pharmaceutical Design 2013; 19 (6) . https://dx.doi.org/10.2174/138161281906140714121225
DOI https://dx.doi.org/10.2174/138161281906140714121225 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Dipeptidyl Peptidase-4 Inhibitor Induced Angioedema – An Overlooked Adverse Drug Reaction?
Current Diabetes Reviews New Ways of Detecting ADRs in Neonates and Children
Current Pharmaceutical Design Editorial [Hot Topic: Advances in Diagnosing Drug Hypersensitivity Reactions (Executive Editors: A. Romano and M. Ventura)]
Current Pharmaceutical Design Therapeutic Progress and Knowledge Basis on the Natriuretic Peptide System in Heart Failure
Current Topics in Medicinal Chemistry Allergic and Pseudoallergic Reactions Induced by Glucocorticoids: A Review
Current Pharmaceutical Design Pharmacogenomics of Asthma
Current Pharmaceutical Design Multi-element Analyses and Chemical-physical Investigations of Food Samples
Current Nutrition & Food Science Antibodies Against Complement System in SLE and their Potential Diagnostic Utility
Current Rheumatology Reviews Ethnicity and Drug Therapy for Hypertension
Current Pharmaceutical Design The Future of Angiotensin II Inhibition in Cardiovascular Medicine
Current Drug Targets - Cardiovascular & Hematological Disorders Complement System in SLE as a Target for Antibodies
Current Rheumatology Reviews Mosquito Allergy and Mosquito Salivary Allergens
Protein & Peptide Letters Complement Activation-Related Pseudoallergy Caused by Amphiphilic Drug Carriers: The Role of Lipoproteins
Current Drug Delivery The Effects of Dehydroepiandrosterone (DHEA) in the Treatment of Depression and Depressive Symptoms in Other Psychiatric and Medical Illnesses: A Systematic Review
Current Drug Targets Mast Cell Disorders In Drug Hypersensitivity
Current Pharmaceutical Design Cross-Reactivity in Cell-Mediated and IgE-Mediated Hypersensitivity to Glucocorticoids
Current Pharmaceutical Design Anabolic-androgenic Steroid use and Psychopathology in Athletes. A Systematic Review
Current Neuropharmacology Novel Therapeutic Approaches and Targets for Treatment of Chronic Urticaria: New Insights and Promising Targets for a Challenging Disease
Current Pharmaceutical Biotechnology Specific Aspects of Drug Hypersensitivity in Children
Current Pharmaceutical Design Advances in Peptide Pharmaceuticals
Current Pharmaceutical Biotechnology